Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

NCT ID: NCT06295965Sponsor: University of WashingtonLast updated: 2026-04-17

Summary

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Detailed description

OUTLINE: This is an observational study. Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.

Arms & interventions

  • OtherNon-Interventional Study

    Non-interventional study

Outcome measures

Primary

  • Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients

    Time frame: Through study completion, up to 5 years

  • Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors

    Measurement Tool: will measure by BM biopsy confirmation done by local hematologist

    Time frame: Through study completion, up to 5 years

  • Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN

    Measurement Tool: the variant allele fraction of the blood clone

    Time frame: Through study completion, up to 5 years

Eligibility criteria

Sex: AllAge: All agesHealthy volunteers: No
Inclusion Criteria: * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and: * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy OR * Subjects who have or have had a solid tumor diagnosis and any of the following: * At least 4 months of exposure to a PARP inhibitor * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm Exclusion Criteria: * Individuals with a life expectancy of less than 6 months

Study locations (1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109

Recruiting
Swisher Lab Research Coordinators · Contact
206-616-8927swisherlabrc@uw.edu
Elizabeth Swisher · Principal Investigator
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study | Cancerify